FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0362							
Estimated average burden								
hours per response:	1.0							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Form 3 Holdings Reported.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Form 4 Transac	tions Reported			or Se	ection 30(h) of the I	nvestment Co	ompany Act	of 1940							
Name and Address of Reporting Person* Sikri Vishal					2. Issuer Name and Ticker or Trading Symbol NEOGENOMICS INC [NEO]						Relationship of Reporting Person(s) to Issuer (Check all applicable) Director					
(Last) (First) (Middle) 9490 NEOGENOMICS WAY					3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2022						X Officer (give title Other (specify below) Selow) President, Pharma Services					
(Street) FORT MYERS FL 33912 (City) (State) (Zip)				4. If Ame	4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Oily)	(State)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date		2. Transaction Date (Month/Day/Yea		Date,	3. Transacti Code (Ins	on (Instr. 3,				Securities Beneficially Ov				rect Indi	ature of rect reficial	
			(Month/Day/Year)		8)	Amount		(A) or (D) Price		F	at end of Issuer's Fiscal Year (Instr. 3 and 4)		(I) (Instr.		Ownership (Instr. 4)	
Common Stock 12/31/2022				L ⁽¹⁾		2	225		\$7.04		148,680		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	onversion Exercise (Month/Day/Year) rice of erivative	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun Securities Underly Derivative Security and 4)		ying	8. Price of Derivative Security (Instr. 5)	9. Num deriva Securi Benefi Owned Follow Report	tive ities icially d /ing	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Title				saction(s)		
Stock Option (Right to Buy)	\$8.42						(2)(3)	06/01/2029	Com	non Stock	319,112		319	9,112	D	

Explanation of Responses:

- 1. These shares were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the year ended December 31, 2022. The shares were acquired in transactions exempt from Section 16b-3.
- 2. On June 1, 2022, Mr. Sikri was granted 193,799 stock options. These options vest ratably over the first two anniversary dates of the grant date.
- 3. On June 1, 2022, Mr. Sikri was granted 125,313 stock options. These options vest ratably over the first four anniversary dates of the grant date.

Remarks:

/s/ Ali Olivo, Attorney-in-Fact 02/01/2023

** Signature of Reporting Person Da

D-4-

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.